CYT 009 GhrQb

Drug Profile

CYT 009 GhrQb

Alternative Names: CYT009-GhrQb; Obesity vaccine - Cytos Biotechnology

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Obesity therapies; Vaccines
  • Mechanism of Action Ghrelin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 Nov 2006 Discontinued - Phase-I/II for Obesity in Switzerland (unspecified route)
  • 31 Mar 2006 Cytos has completed enrolment in a phase I/IIa trial for Obesity in Switzerland
  • 11 May 2005 Phase-I/II clinical trials in Obesity in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top